Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Re-evaluating the Regulation of Human Genome Editing in Canada
FY 2019-20
Summary
"Though genome editing has tremendous potential for the treatment of disease, this emerging technology has elicited much concern in the scientific community and the public at large. The speed of modern scientific progress, such as the refinement of genome editing technology, presents a serious challenge for ethicists and policy makers. Given the pace of development of genetic engineering technology, the Canadian health policy and regulatory framework may not adequately regulate its use in humans nor address its potential risks. There are currently no regulations or guidelines specifically addressing somatic genome editing for the purpose of therapy, though gene therapy drugs must comply with the Food and Drug Regulations. Germline genome editing, on the other hand, is criminally banned under the Assisted Human Reproduction Act, despite its therapeutic potential. I propose to study the social and ethical consequences of employing genome editing technology in humans, and the implications for Canadian law and policy. I will first identify the ethical risks of genetic engineering in humans by reviewing the academic literature on both somatic and germline genome editing. I will then look at the legal and regulatory framework in Canada and examine the current laws and policies relevant to this issue, allowing me to identify any gaps in the Canadian framework. Finally, I will compare our framework to that of other countries to gain insight into how our system could be improved. This study will improve our understanding of the strengths and weaknesses of the existing regulatory framework. This knowledge will contribute to efforts to improve the framework such that Canadians may benefit from emerging genome editing technologies while being protected from unnecessary risks."
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428717
Name
Bradbury-Jost Jacqueline M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Re-evaluating the Regulation of Human Genome Editing in Canada
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Assisted Human Reproduction Act; Crispr/Cas9; Determinants Of Health; Food And Drug Regulations; Genetic Engineering; Genome Editing; Genomics; Health Equity; Health Policy; Prime Editing
Abstract
"Though genome editing has tremendous potential for the treatment of disease, this emerging technology has elicited much concern in the scientific community and the public at large. The speed of modern scientific progress, such as the refinement of genome editing technology, presents a serious challenge for ethicists and policy makers. Given the pace of development of genetic engineering technology, the Canadian health policy and regulatory framework may not adequately regulate its use in humans nor address its potential risks. There are currently no regulations or guidelines specifically addressing somatic genome editing for the purpose of therapy, though gene therapy drugs must comply with the Food and Drug Regulations. Germline genome editing, on the other hand, is criminally banned under the Assisted Human Reproduction Act, despite its therapeutic potential. I propose to study the social and ethical consequences of employing genome editing technology in humans, and the implications for Canadian law and policy. I will first identify the ethical risks of genetic engineering in humans by reviewing the academic literature on both somatic and germline genome editing. I will then look at the legal and regulatory framework in Canada and examine the current laws and policies relevant to this issue, allowing me to identify any gaps in the Canadian framework. Finally, I will compare our framework to that of other countries to gain insight into how our system could be improved. This study will improve our understanding of the strengths and weaknesses of the existing regulatory framework. This knowledge will contribute to efforts to improve the framework such that Canadians may benefit from emerging genome editing technologies while being protected from unnecessary risks."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bradbury-Jost, Jacqueline M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~